MedPath

J&J's Icotrokinra Achieves Phase III Success in Psoriasis Treatment

• Johnson & Johnson's icotrokinra demonstrated significant skin clearance and tolerability in Phase III trials for psoriasis treatment. • The oral, once-daily pill could offer an industry-leading combination of efficacy and safety for patients. • Icotrokinra's success positions it as a potential novel treatment option in the psoriasis market, addressing unmet needs.

Johnson & Johnson (J&J) has announced positive results from its Phase III clinical trials for icotrokinra, an oral, once-daily pill aimed at treating psoriasis. The company reports that icotrokinra has demonstrated a significant combination of skin clearance and tolerability, potentially setting a new standard in psoriasis treatment.
The successful late-stage trials suggest that icotrokinra could become a leading option for patients seeking effective and convenient treatment. The specific details of the trial, including the patient population, dosing regimens, and primary/secondary endpoints, will be crucial in understanding the full scope of icotrokinra's potential. Further data releases and presentations are anticipated to provide more in-depth insights into the clinical profile of the drug.
The current psoriasis treatment landscape includes a range of topical and systemic therapies, but unmet needs remain, particularly in achieving both high efficacy and good tolerability with oral medications. Icotrokinra's Phase III success suggests it may fill this gap, offering a novel approach to managing psoriasis.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Icotrokinra Shows Promise in Phase 3 Trials for Plaque Psoriasis

Icotrokinra, an oral peptide targeting the IL-23 receptor, met primary endpoints in two Phase 3 trials for moderate-to-severe plaque psoriasis.
The ICONIC-LEAD trial demonstrated that 64.7% of patients achieved clear or almost clear skin at week 16, significantly higher than placebo.

Protagonist Therapeutics' Oral Icotrokinra Achieves Positive Phase 3 Results for Plaque Psoriasis

Protagonist Therapeutics' icotrokinra, an oral peptide drug, demonstrated significant skin clearance in Phase 3 trials for moderate-to-severe plaque psoriasis.
The ICONIC-LEAD study showed 65% of patients achieved clear skin (IGA 0 or 1) at week 16 with icotrokinra, compared to 8% in the placebo group.

Icotrokinra Shows Promise as Oral Treatment for Plaque Psoriasis in Phase 3 Trial

Icotrokinra, an oral peptide drug blocking the IL-23 receptor, demonstrated significant clearance of psoriatic plaques in a Phase 3 trial.
65% of patients achieved clear skin (IGA score of 0 or 1) at week 16 with icotrokinra, compared to 8% in the placebo group.

JNJ-2113 Demonstrates Significant Skin Clearance in Phase 3 Psoriasis Trials

Phase 3 trials ICONIC-LEAD and ICONIC-TOTAL showed JNJ-2113 significantly improved skin clearance in moderate-to-severe plaque psoriasis patients compared to placebo.
In ICONIC-LEAD, 64.7% of patients on JNJ-2113 achieved IGA 0/1 at week 16, versus 8.3% on placebo, with PASI 90 achieved by 49.6% versus 4.4%, respectively.

Oral JNJ-2113 Demonstrates Efficacy in Phase 3 Trials for Moderate-to-Severe Psoriasis

JNJ-2113 (icotrokinra), an oral IL-23 receptor antagonist, showed significant skin clearance in phase 3 ICONIC-LEAD trial compared to placebo for moderate-to-severe psoriasis.
The ICONIC-TOTAL study also met its primary endpoint, demonstrating JNJ-2113's efficacy in treating psoriasis affecting special areas like the scalp, genitals, hands, and feet.

JNJ-2113 Shows Promising Phase 3 Results for Plaque Psoriasis

Phase 3 trials ICONIC-LEAD and ICONIC-TOTAL showed JNJ-2113 significantly improved skin clearance in moderate to severe plaque psoriasis patients.
In ICONIC-LEAD, 64.7% of JNJ-2113 patients achieved IGA 0/1 at week 16, compared to 8.3% on placebo, with sustained improvement at week 24.

Johnson & Johnson's Oral IL-23 Inhibitor Icotrokinra Shows Promise in Phase 3 Psoriasis Trials

Johnson & Johnson's oral drug icotrokinra demonstrated significant skin clearance in Phase 3 trials for moderate-to-severe plaque psoriasis.
In the ICONIC-LEAD study, icotrokinra achieved clear or almost clear skin in approximately two-thirds of participants after four months.

J&J's Oral IL-23 Inhibitor Icotrokinra Achieves Positive Phase 3 Results in Psoriasis

Johnson & Johnson's icotrokinra met primary endpoints in the ICONIC-LEAD phase 3 trial, demonstrating significant skin clearance in psoriasis patients.
After 16 weeks, 64.7% of patients achieved clear or almost clear skin (IGA 0/1), and 49.6% showed a 90% or greater improvement in PASI score.

Icotrokinra Shows Promising Phase 3 Results for Moderate to Severe Plaque Psoriasis

Johnson & Johnson's icotrokinra (JNJ-2113), a novel oral IL-23 receptor antagonist, met its co-primary endpoints in Phase 3 trials for moderate to severe plaque psoriasis.
The ICONIC-LEAD study showed 74.1% of patients achieved clear or almost clear skin (IGA 0/1) at week 24, with 64.9% achieving PASI 90.

Icotrokinra Shows Promising Phase 3 Results for Plaque Psoriasis Treatment

Phase 3 trials show Icotrokinra significantly improved skin clearance in adults and adolescents with moderate to severe plaque psoriasis.
At week 16, 64.7% of patients achieved clear or almost clear skin (IGA 0/1) with Icotrokinra, compared to 8.3% on placebo.

Reference News

[1]
J&J Psoriasis Pill In A Tier Of Its Own After Phase III Win - Citeline
insights.citeline.com · Nov 19, 2024

J&J's icotrokinra, a psoriasis treatment, achieved significant skin clearance with demonstrated tolerability in Phase II...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy